Drugs / intravenous immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01545518 | Nov 2011 → Jun 2013 | autoimmune disorder of the nervous system, focal epilepsy, limbic encephalitis | Emory University | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunoglobulin | “immune treatment with a compound called intravenous immunoglobulin (IVIG)” NCT01545518 ↗ |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01545518 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin (IVIG)” NCT01545518 ↗ |
| Route | Intravenous | “intravenous immunoglobulin (IVIG)” NCT01545518 ↗ |